Picture [LSE] – The Business Web Portal 600x60px
Document › Details

Merck KGaA. (11/19/18). "Press Release: Syntropy to Unlock the Value of Scientific Data in Fight to End Cancer. Joint Venture between Merck and Palantir Technologies Being Created to Advance Cancer Research". Palo Alto, CA.

Organisation Organisation Merck KGaA
  Group Merck (DE) (Group)
Products Product software
  Product 2 cancer drug
Person Person Oschmann, Stefan (Merck (DE) 201604– CEO before Executive Board Member since 2011 before MSD)

> To empower scientists and research centers with the leading data integration and analytics technology

> To allow users to collaborate to drive scientific discovery, while ensuring control, ownership and traceability of their data

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syntropy. Syntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives.

Research institutions around the world are generating a rapidly growing amount of biomedical data, but much of it is trapped in silos within and between institutions. Today, this critical data is often inaccessible to the scientists and clinicians who need it to advance their work. Syntropy aims to unlock the value of this untapped data, enabling the world’s leading experts to collaborate in the fight against cancer and many other diseases.

„The success of science hinges on the ability to act on insights,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “We expect Syntropy to facilitate collaboration within the global scientific community, in order to drive breakthrough innovation in cancer research.”

“Unlocking the power of scientific data is critical to advancing the fight against cancer,” said Alexander Karp, Palantir co-founder and CEO. “Syntropy aims to help researchers collaborate securely to realize the value of this data, driving discoveries that will deliver better treatments to patients faster.”

Syntropy’s user-centric data integration platform is powered by Palantir Foundry, which allows users to structure and analyze data from disparate sources, enabling experts to more quickly act on novel research insights and advance patient care, while safeguarding data ownership. Syntropy is expected to also facilitate the secure, transparent sharing of data between participating researchers and institutions, creating an ecosystem that incentivizes collaboration and ultimately accelerates scientific discovery.

For more information about Syntropy, visit

For more information, please contact Friederike Segeberg
+49 6151 72 6328

About Syntropy

Syntropy shall be a joint venture between a new subsidiary of Merck, which is independent from its existing healthcare, life science and performance materials business sectors, and Palantir Technologies, aimed at unlocking the value of scientific biomedical data. Syntropy is expected to serve as a catalyst for change in scientific research by equipping scientists with more intuitive and effective tools for unlocking the value of their data, while creating an ecosystem that brings together leading scientific experts to win the fight against cancer and countless other diseases. Syntropy is expected to be headquartered in Boston, MA. Merck and Palantir Technologies have signed a non-binding term sheet to initiate the creation of Syntropy.

About Merck

Merck, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 53,000 employees work to make a positive difference to millions of peoples’ lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enable the intelligence of devices – the company is everywhere. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1666, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, visit

About Palantir

Palantir Technologies is a software company that builds enterprise data platforms for organizations with highly complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combatting terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Palantir is headquartered in Palo Alto, with major offices in New York, Washington, D.C., London, Paris, and Munich. For more information about Palantir Technologies, visit

Forward-Looking Statements

This communication contains “forward-looking statements”. Forward-looking statements may be identified by words such as “intent,” “will,” “shall,” “aims,” “is expected” and similar expressions. These forward-looking statements are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from the results implied in this communication. We expressly disclaim any obligation to update such statements, except as required by law.

Record changed: 2018-11-22


Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px

» top